Following Chinese adults with hypertrophic cardiomyopathy in everyday care
Observes adults with thickened heart muscle, hypertrophic cardiomyopathy, with no treatment given.
Plain-language title generated from the registry record
Registry title: A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population
Key facts
- Where
- Hangzhou, ChinaSee the 2 sites
Where in China
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, ChinaHangzhou, ChinaNot yet recruiting
- Second Affiliated Hospital, Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT06775665
- Record updated
- 15 September 2026
- Original description
This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.Read full original descriptionShow less
Clinical Characteristics and Real-World Outcomes of Chinese Patients With Hypertrophic Cardiomyopathy: A Prospective Cohort Study
This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.
Inclusion: Willing and able to provide written informed consent (ICF) and any required privacy authorization before the start of the study; Aged ≥18 years at the time of signing the written informed consent; Diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, meeting the following criteria:; Left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (MRI); Left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family; Exclusion of other cardiovascular diseases or systemic/metabolic diseases causing ventricular wall thickening.
Exclusion: Uncontrolled primary hypertension; Moderate or severe aortic valve stenosis and/or primary mitral valve disease with severe mitral regurgitation; Confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., Fabry disease, amyloidosis); Severe infections, liver failure, renal failure, or other life-threatening conditions; Expected life expectancy <1 years.